Cardiovascular devices maker Artivion Q3 revenue beats estimates on growth in stent grafts

Overview

• Artivion Q3 revenue grows 18% yr/yr, beating analyst expectations

• Adjusted net income for Q3 beats analyst expectations

• Company enrolls first patient in ARTIZEN trial, marking strategic progress

Outlook

• Artivion raises full-year 2025 revenue guidance to $439 mln-$445 mln

• Company expects 2025 adjusted EBITDA to grow 24%-28%

• Artivion anticipates slightly positive currency impact for 2025

Result Drivers

• PRODUCT GROWTH - Revenue growth driven by 38% increase in stent grafts and 25% increase in On-X, compared to Q3 2024

• FINANCIAL RESTRUCTURING - Refinanced credit agreement to extend maturity date to 2031 and secure a more favorable interest rate

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Artivion Inc is $46.00, about 1.1% below its November 5 closing price of $46.51

• The stock recently traded at 139 times the next 12-month earnings vs. a P/E of 100 three months ago

Press Release: ID:nPn1NRcjTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.